Additionally, in vivo targeting of the FRα has been reported in several studies, of which Tummers et al. described the feasibility of the detection of primary breast and ovarian cancer using EC17, including the aim to detect LNMs in vivo. This evidence concerns the gene FOLR1 and ovarian cancer.